Actively Recruiting
Evaluating Obudanersen Treatment for Angelman Syndrome in Children and Adults Due to Paternal Uniparental Disomy or Imprinting Defects
Led by Ionis Pharmaceuticals, Inc. · Updated on 2026-10-20
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating obudanersen in people with Angelman syndrome AS caused by paternal uniparental disomy or imprinting defects. This Phase 3 study aims to assess the treatments effect on expressive communication in children and adults with AS, focusing on those aged 2 to 50 years. The study is open-label with a single treatment group and includes two age-based cohorts, with more participants expected in the pediatric group. Participants receive obudanersen through an injection into the spinal fluid every 12 weeks during two main periods a Treatment Evaluation Period lasting about 60 weeks, followed by a Long-Term Extension period of 101 weeks. After these, there is an 8-month Post-Treatment Follow-up phase. The study involves intrathecal bolus injections at regular intervals throughout these periods. During the study, participants will undergo various assessments including expressive communication evaluations using the Bayley Scales for Infant and Toddler Development and other behavior and adaptive skill measures at baseline and week 52. Caregiver-reported outcomes and clinical evaluations will monitor progress and safety. The total involvement spans multiple years, including treatment, long-term extension, and follow-up to thoroughly assess the treatment impact and safety over time.
CONDITIONS
Brief Title
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)
Research Team
I
Ionis Pharmaceuticals, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here